Cardio Diagnostics said the final gapfill payment rate of $854 for both tests is an increase from the preliminary gapfill ...
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), a leader in artificial intelligence-driven precision cardiovascular medicine tests, and Family Medicine Specialists (FMS), a ...
Cardio Diagnostics Holdings Inc. (NASDAQ:CDIO), an AI-powered precision cardiovascular medicine company, is making progress in gaining broad access to Medicare reimbursement for its Epi+Gen CHD™ and ...
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics, Inc, a biotechnology company making cardiovascular disease prevention and early detection more accessible, personalized and precise, announces the launch ...
Obtaining the payment rates marks a key milestone in gaining broad access to Medicare reimbursement. CHICAGO--(BUSINESS WIRE)-- Cardio Diagnostics Holdings, Inc. (CDIO) (Nasdaq: CDIO), an AI-powered ...
Cardio Diagnostics Enters Into an Agreement with AGEPHA Pharma to Advance Precision Assessment and Management of Inflammation Associated with Coronary Heart Disease AGEPHA Pharma will supply LODOCO® ...
NEW YORK, Aug. 31 (UPI) --A single blood test that measures inflammation and fat can predict women's risk for cardiovascular disease 30 years later, a new Harvard study suggests. The findings, ...
A blood biomarker yet to be used in cardiac arrest care can give a clearer picture of the extent of brain damage after a ...
Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), an AI-powered precision cardiovascular medicine company, today announced that the Centers for Medicare and Medicaid Services (CMS) has issued a final ...
A blood biomarker yet to be used in cardiac arrest care can give a clearer picture of the extent of brain damage after a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback